This is the authors' abstract. We don't add key points for this paper.
PD-L1 expression is consistently associated with worse survival, regardless of how it is quantified. In addition to acting as a prognostic biomarker, PD-L1 may also be used in future as a predictive biomarker for patients most likely to benefit from adjuvant immunotherapy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Tuminello et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: